Chardan Capital analyst Keay Nakae maintained Dyne Therapeutics with a Buy and lowered the price target from $50 to $38.

Dyne also reported new positive long-term data from adult DM1 patients enrolled in the randomized, placebo-controlled multiple ascending dose (MAD) portion of the DYNE-101 ACHIEVE trial, including ...

See the latest Jyong Biotech Ltd stock price (MENS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.

Stay up-to-date on CID HoldCo, Inc. Common Stock (DAIC) news with the latest updates, breaking headlines, news articles, and more from around the web at Nasdaq.com.